Cyclopharm Limited, the Australian-based radiopharmaceutical company, has taken a significant step in its US expansion efforts by signing an agreement with the United States Department of Veterans Affairs (VA) and receiving its first order from the US Department of Defense (DoD). This deal marks a pivotal moment for Cyclopharm as it continues to roll out […]
The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils. This marks the first time Dupixent, jointly developed by Sanofi and Sanofi and Regeneron, is approved for this specific patient group within the European […]
Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that encompasses emphysema and chronic bronchitis, often leading to severe respiratory issues. Affecting approximately 30 million individuals in the United States alone, with half remaining undiagnosed, COPD poses significant health risks including accelerated disease progression and heart complications without proper treatment. This article delves […]
In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation. This collaboration aims to enhance healthcare access by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for COPD patients in the US. […]
Lupin has announced that its subsidiary in Canada, Lupin Pharma Canada has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD) in Canada. Tiotropium Bromide Inhalation Powder is used as a long-term maintenance bronchodilator for patients with COPD, including […]
Lupin Limited has agreed to acquire all rights to a couple of inhalation medicines, namely Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals for $75 million. The Indian pharma company anticipates the deal to be incremental to earnings in the first year. According to Lupin, the acquisition of […]
Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic version of Spiriva (Tiotropium bromide). Lutio has been approved for the treatment of chronic obstructive pulmonary disease (COPD). It is the second inhalation product for the British market from Lupin […]
Zydus Group said that its subsidiary Zydus Pharmaceuticals (USA) has secured final approval from the US Food and Drug Administration (FDA) to market Roflumilast Tablets in 500mcg strength and tentative approval for Roflumilast Tablets in 250mcg. Roflumilast Tablets is the generic version of Dalires. Zydus said that as it is one of the first applicants […]
Lupin Limited said that its subsidiary Lupin Healthcare (UK) has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Luforbec (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pressurized metered dose inhaler (pMDI). Vinita Gupta – CEO of Lupin Limited said: “We are truly delighted to receive the first marketing authorization for generic Fostair […]
Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler. As per data from IQVIA, Tiotropium DPI’s market size was $450 million in the European […]